REG - Seneca Growth Cap. Seneca Growth-SVCT - Updated NAV & Ordinary Share Class Dividend

Seneca Growth Capital VCTAnnouncement

Yesterday 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251015:nRSO5441Da&default-theme=true

RNS Number : 5441D  Seneca Growth Capital VCT PLC  15 October 2025

Updated Net Asset Values and Ordinary Share Class Dividend Declaration

Seneca Growth Capital VCT Plc

15 October 2025

 

Seneca Growth Capital VCT Plc

Unaudited Net Asset Value ("NAV") Update as at 30 September 2025

The Directors of Seneca Growth Capital VCT Plc (the "Company") and the
Investment Manager of the Company, Seneca Partners Limited ("Seneca"), have
reviewed the valuation of the Company's investment portfolios for the quarter
ending 30 September 2025 and announce an updated NAV for each of the Company's
Ordinary and B share classes as at 30 September 2025.

For the purposes of calculating the NAV per share for both share classes,
quoted investments are valued in line with closing bid prices as at 30
September 2025 and unquoted investments are carried at fair value.
 

B share NAV as at 30 September 2025

As at 30 September 2025, the unaudited B share NAV was 47.7p per share, a 2%
decrease from the previously published unaudited NAV as at 30 June 2025 of
48.7p.

The B share NAV Total Return was 67.2p compared to 68.2p as at 30 June 2025.

The 1.0p decrease in NAV per B share in the quarter is principally due to
movements in the share prices of the B share pool's AIM/AQSE quoted investee
companies during the quarter.

Ordinary share NAV as at 30 September 2025

As at 30 September 2025, the unaudited Ordinary share NAV was 13.1p per share,
a 16% increase from the previously published unaudited NAV as at 30 June 2025
of 11.3p.

The Ordinary share NAV Total Return was 89.4p compared to 87.6p as at 30 June
2025.

The 1.8p increase in NAV per Ordinary share is principally due to the increase
in the share price of AIM quoted Arecor Therapeutics Plc ("Arecor") and
Scancell Holdings Plc ("Scancell").

Scancell was the largest holding in the Ordinary share portfolio, representing
92% of the Ordinary share NAV as at 30 June 2025. As a result, the Ordinary
share NAV moved largely in line with the movement in the Scancell share price
during the quarter. The Company was presented with an opportunity to de-risk
the concentration of the holding for Ordinary shareholders and was able to
achieve a profitable exit of c.47% of the Ordinary share pool's holding as at
30 June 2025. Seneca was able to realise £435k in proceeds from the disposal,
which generated a profit of £172k, resulting in an average weighted return of
1.7x on original investment cost. This disposal has enabled the Company to
declare a second interim capital dividend of 5.0p per Ordinary share.

The Ordinary share pool's unquoted investments have all previously been
written down to £nil carrying value. The valuations of the Ordinary share
pool's unquoted investments remain unchanged as at the quarter end.

Second Interim Capital Dividend on Ordinary Shares

The Directors of the Company are pleased to declare an interim capital
dividend of 5.0 pence per Ordinary Share for the year to 31 December 2025, to
be paid on 7 November 2025.

The ex-dividend date is 23 October 2025.

The record date for the dividend is 24 October 2025.

The dividend payment date is 7 November 2025.

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation No 596/2014 which is part of English
Law by virtue of the European (Withdrawal) Act 2018, as amended. Upon the
publication of this announcement via a Regulatory Information Service, this
information is now considered to be in the public domain.

For further information, please contact:

Richard Manley, Seneca Growth Capital VCT Plc
at Richard.Manley@senecapartners.co.uk
(https://www.globenewswire.com/Tracker?data=NYKct9x-DdsR4QlY-jiKdr4Ds343jrNSyEXWQye6ucOhw8oWN7dLX3Wdcp9KF6TbOEX9YclvOiw00HyPvanWTlHJEzgT7hPFUP7TnZ9O7VvByTXAuKURKYfsr-5q24JJ9xwQa2Xf_YOGlg2N1k2rKrEi1H1bMjDGkOEXXJ8Un5eeGtOIZZ0vG0eD9EoQyPVuNNmvxO9G3JpIjKfnOa8cYsHqVUe-4slaAZJEt7BE0WXY-AFpQUszcAbCWQfn5UBSDECui99mReRpMPzgb5xpntdisqA-ABSXghhSP3nMjofRa7kB8rhETAesKQJD1wcTxaEQKdFkNN0C3J79rAO7gFXGQ0X_b9xy1fMs-IKzKJJH4Bk9YSFv0Pzi7pFhsEixTiHcTaAaal_ErptCEYFfEjsBVoXw3Y5Y85HeaQoQLLY3nXLEQfaaxEtr8H72Tfz1Pv4lfa8A5L8uZ91m-jFjovP0nTB-bCw1NRNwxSh19ednjtfwW0CGOQ24CfEj_SBdTGnk_8QgL1NyhtyMay2F1RpiIJRzfbN_yKRZIFmeOOcwdJE3S_eZVMYXcniLu5McwV_Gp4G_0edLzQTWMPrLCc8KRbftcxWc5SessufPY5o=)

Siobhan Pycroft, Seneca Partners Limited at
Siobhan.Pycroft@senecapartners.co.uk
(mailto:Siobhan.Pycroft@senecapartners.co.uk)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NAVPKPBBPBDDBKD



            Copyright 2019 Regulatory News Service, all rights reserved